Last edition
News about "Systemic Sclerosis"
Aisa Pharma Gets FDA Orphan Drug Designation for AISA-021
Aisa is developing AISA-021 for the treatment of Systemic Sclerosis (SSc), a rare disease, which impacts approximately 175,000 Americans and has the highest mortality rate of any autoimmune disease.
Systemic Sclerosis | 10/09/2024 | By Aishwarya | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members